Medical uses of marijuana (Cannabis sativa): fact or fallacy?

References

• Abel EL. Marihuana: The First Twelve Thousand Years. New York: Plenum Press, 1980.
   Google Scholar
• Hall WD, Pacula R. Cannabis Use and Dependence: Public Health and Public Policy. Cambridge: Cambridge University Press, 2010.
   Google Scholar
• Oriani-Ambrosini MG. Medical Innovation Bill (proposed section 75 Bill). Republic of South Africa Government Gazette No. 37349, February 2014.
   Google Scholar
• Eddy M. Medical Marijuana: Review and analysis of federal and state policies. CRS Report for Congress RL33211. 2010 (http://assets.opencrs.com/rpts/RL33211_20100402.pdf).
   Google Scholar
• National Conference of State Legislatures. State Medical Marijuana Laws. 2013 (www.ncsl.org/research/health/state-medical-marijuana-laws.aspx).
   Google Scholar
• van Os J, Krabbendama L, Myin-Germeysa Inez, Delespaula P. The schizophrenia envirome. Curr Opin Psychiatry 2005; 18 (2): 141–5.
   PubMed Web of Science ®Google Scholar
• van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468 (7321): 203–12.
   PubMed Web of Science ®Google Scholar
• Heishman SJ, Arastech K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory and performance. Pharmacol Biochem Behav 1997; 58 (1): 93–101.
   PubMed Web of Science ®Google Scholar
• Solowij N. Cannabis and Cognitive Functioning. Cambridge: Cambridge University Press, 1998.
   Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriquez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers 2007; 4 (8): 1678–92.
   PubMed Web of Science ®Google Scholar
• Development and Approval Process (Drugs). FDA and Marjiuana Questions and Answers (www.fda.gov/drugs/developmentapprovalprocess/ucm401890.htm).
   Google Scholar
• Clinical Trials (PDQ). Evaluation prospectively the level of reduction in cognitive functions of cancer patients who are on active oncology treatments and use cannabis. The second goal is to identify high-risk groups for cognitive impairment due to cannabis use. National Cancer Institute, 2014 (ClinicalTrials.govdatabase).
   Google Scholar
• Lewin L. PHANTASTICA. Narcotic and stimulating drugs their use and abuse. London: Routledge and Kegan Paul, 1931.
   Google Scholar
• Walton RP. Marijuana. America's new drug problem. New York: Lippincott, 1938.
   Google Scholar
• Robinson R. The Great Book of Hemp. Rochester, VT: Park Street Press, 1996.
   Google Scholar
• Mathre ML. Cannabis in Medical Practice. Jefferson, NC: MacFarland, 1997.
   Google Scholar
• Mechoulam R. The pharmochemistry of Cannabis sativa. In: Mechoulam R ed. Cannaboids as therapeutic agents. Boca Raton, FL: CRC Press, 1986: 1–19.
   Google Scholar
• Wright J. The drugs situation in South Africa-drug trafficking in South Africa and trends in the southern sub-region of Africa. Drugs Arena 12/91, 1991.
   Google Scholar
• MacDonald D. Drugs in southern Africa: an overview. In: Drugs: education, prevention and policy 1996: Vol 3, No 2.
   Web of Science ®Google Scholar
• Warkany J. Why I doubted that thalidomide was the cause of the epidemic of limb defects of 1959 to 1961. Teratology 1988; 38 (3): 217–9.
   PubMedGoogle Scholar
• Miller T M, Strömland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 1999; 60 (5): 306–21.
   PubMedGoogle Scholar
• Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38 (3): 203–15.
   PubMedGoogle Scholar
• Kelsey FO. Thalidomide update: regulatory aspects. Teratology 1988; 38 (3): 221–6.
   PubMedGoogle Scholar
• Prescription for Addiction: the AZ and CA medical Drug Use Initiatives Hearing before the Senate Judiciary Committee, 1996. In: CIS-Congressional Universe (www.library.arizona.edu/library/teams/sst/pol/guide/cis-legislation.htm#hearings).
   Google Scholar
• New York Times. Marijuana and medical marijuana, 2011 http://topics.nytimes.com/top/reference/timestopics/subjects/m/marijuana/index.html).
   Google Scholar
• Clark PA. The ethics of medical marijuana: government restrictions vs. medical necessity. J Public Health Policy 2000; 21 (1): 40–60.
   PubMed Web of Science ®Google Scholar
• Medical Marijuana ProCon. Public policy about medical marijuana. Would allowing the medical use of marijuana send the wrong message to our children and our society, 2006? (www.medicalmarijuanaprocon.org/bin/procon/procon.cgi?sdatabase=5H-Subs-1.db&command=viewone&op=t&id-4&rnd=846.236751972751).
   Google Scholar
• Schrag P. A quagmire for our time. The war on drugs. J Public Health Policy 2002; 23 (3): 286–98.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebocontrolled trial. Neurology 2007; 68 (7): 515–21.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Toperoff W, Vaida F et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized crossover clinical trial. Neuropsychopharmacology 2009; 34 (3): 672–80.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Tsodikov A et al. A randomized, placebo controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9 (6): 506–21.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94 (2): 149–58.
   PubMed Web of Science ®Google Scholar
• Wallace M, Schulteis G, Atkinson JH et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107 (5): 785–96.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro H et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182 (14): E694–701.
   PubMed Web of Science ®Google Scholar
• Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannaboids an effective and safe treatment option in the management of pain? A qualitative review. BMJ 2001; 323 (7303): 13–6.
   Google Scholar
• Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18 (1): 84–9.
   PubMed Web of Science ®Google Scholar
• Grifo F, Newman D, Fairfield A, Bhattacharya B, Grupenhoff JT. The origins of prescription drugs. In: Grifo F, Rosenthal J eds. Biodiversity and Human Health. Washington DC: Island Press, 1997: 131–63.
   Google Scholar
• National Center for Complementary and Alternative Medicine. Statistics on CAM use in the United States, 2007 (http://nccam.nih.gov/news/camstats/2007).
   Google Scholar
• Center for Medicine & Medicaid Services. National Health Expenditure Projections 1960–2008 (www.cms.gov/nationalhealthexpenddata/02_national).
   Google Scholar
• Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997–2002. Altern Ther Health Med 2005; 11 (1): 42–9.
   PubMed Web of Science ®Google Scholar
• National Center for Complimentary and Alternative Medicine. Statistics on CAM Costs (http://nccam.nih.gov/news/camstats/costs).
   Google Scholar
• Angell M, Kassirer JP. Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 1998; 339 (12): 839–41.
   PubMed Web of Science ®Google Scholar
• United Nations. Department of Economic and Social Affairs. Population Division. World Prospects. The 2010 Revision. (http://esa.un.org/unpd/wpp).
   Google Scholar
• Grinspoon L, Bakalar JB. Marijuana: the forbidden medicine. New Haven: Yale University Press. 1993.
   Google Scholar
• Center For Medicinal Cannabis Research 2014, University of California (www.cmcr.ucsd.edu).
   Google Scholar
• Grant I, Hampton Atikinson J, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J 2012; 6: 18–25.
   PubMedGoogle Scholar
• Huestis MA. Pharmacokenetics and metabolism of the plant cannabinoids, delta-8-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; 168: 657–90.
   PubMedGoogle Scholar
• Pletcher MJ, Vittinghoff E, Kalhan R et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012; 307 (2): 173–81.
   PubMed Web of Science ®Google Scholar
• Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13 (6): 669–71.
   PubMed Web of Science ®Google Scholar
• Petro D, Ellenberger Jr C. Treatment of human spasticity with delata-9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21 (8–9 Suppl): 413S–416S.
   PubMed Web of Science ®Google Scholar
• Ungerleider JT, Andrysiak TA, Fairbanks I, Ellison GW, Meyers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7 (1): 39–50.
   PubMedGoogle Scholar
• Zajicek J, Fox P Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362 (9395): 1517–26.
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329 (7460): 253.
   PubMed Web of Science ®Google Scholar
• Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336 (7637): 199–201.
   PubMed Web of Science ®Google Scholar
• Tramer MR, Caroll D, Campbell FA, Retnolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323 (7303): 16–21.
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006; 105 (1–2): 1–25.
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (2): 89–97.
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Laubenstein L et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14 (1): 7–14.
   PubMed Web of Science ®Google Scholar
• Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 1996; 39: 197–221.
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PI et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310 (5746): 329–32.
   PubMed Web of Science ®Google Scholar
• Martin BR, Wiley JL. Mechanism of action of cannibinoids: how it may lead to treatment of cachexia, emesis and pain. J Support Oncol 2004; 2 (4): 305–16.
   PubMedGoogle Scholar
• Morrow GR, Roscoe JA, Hickok JT et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 1998; 12 (3 Suppl 4): 32–7.
   Google Scholar
• Fujii Y, Toyooka H. Current prevention and treatment of postoperative nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists: a review. J Anesth 2001; 15 (4): 223–32.
   PubMedGoogle Scholar
• Higgins SC, Montgomery GH, Bovbjerg DH. Distress before chemotherapy predicts delayed but not acute nausea. Support Care Cancer 2007; 15: 171–7.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol 2007; 36 (1): 45–9.
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17 (1): 21–9.
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10 (4): 417–24.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10 (4): 434–41.
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104 (5):1040–6.
   PubMed Web of Science ®Google Scholar
• Abrams DJ, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007; 82 (5): 572–8.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young C. A Randomized controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65 (6): 812–9.
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised double-blind, placebo-controlled clinical trial. Pain 2007; 133 (1–3): 210–20.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Agency. The DEA Position on Marijuana. January 2011 (www.dea.gov/docs/marijuana_position_2011.pdf).
   Google Scholar
• United Nations Office on Drugs and Crime, Regional Office for Southern Africa. Strategic Programme Framework on Crime and Drugs for Southern Africa, 2003 (www.sahealthinfo.org/admodule/docsauthor.htm).
   Google Scholar
• MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry 2001; 178: 123–8.
   PubMed Web of Science ®Google Scholar
• Single E, Christie P, Ali R. The impact of cannabis decriminalisation in Australia and the United States. J Public Health Policy 2002; 21 (2): 157–86.
   Web of Science ®Google Scholar
• Wodak A, Reinarman C, Cohen PD, Drummond C. Cannabis control: costs outweigh the benefits. BMJ 2002; 324 (7329): 105–6.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Lynskey MT, Madden PA. Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 2003; 60 (10): 1033–9.
   PubMed Web of Science ®Google Scholar
• Ashbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344: e536.
   PubMed Web of Science ®Google Scholar
• Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Palliat Care Pharmocother 2009; 23 (1): 4–25.
   PubMedGoogle Scholar
• Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmocother 2009; 23 (2): 120–40.
   PubMedGoogle Scholar